Organogenesis Holdings (ORGO) said late Monday the independent data monitoring committee for its second phase 3 trial of ReNu to manage symptoms related to knee osteoarthritis recommended that the study proceed without modification and without increase to the sample size.
The committee also found the safety data to be consistent with the known safety profile for ReNu, the company said.
The 594-patient trial involves the ReNu amniotic suspension allograft to treat moderate to severe symptomatic knee osteoarthritis, a degenerative joint disease
The company's shares were up more than 5% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。